1017898-78-0

Basic information

• Product Name: (2E)-1-(2,4,6-trimethoxyphenyl)-3-(4-chlorophenyl)-2-propen-1-one
• Synonyms: (2E)-1-(2,4,6-trimethoxyphenyl)-3-(4-chlorophenyl)-2-propen-1-one
• CAS NO: 1017898-78-0
• Molecular Weight: 332.784
• Mol File: 1017898-78-0.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (2E)-1-(2,4,6-trimethoxyphenyl)-3-(4-chlorophenyl)-2-propen-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-1-(2,4,6-trimethoxyphenyl)-3-(4-chlorophenyl)-2-propen-1-one(1017898-78-0)
• EPA Substance Registry System: (2E)-1-(2,4,6-trimethoxyphenyl)-3-(4-chlorophenyl)-2-propen-1-one(1017898-78-0)

Safety Data

• Hazardous Substances Data: 1017898-78-0(Hazardous Substances Data)

Upstream product

• 99-91-2 para-chloroacetophenone 
• 832-58-6 1-(2,4,6-trimethoxyphenyl)ethanone 
• 480-66-0 2,4,6-trihydroxyacetophenone 
• 108-73-6 3,5-dihydroxyphenol 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 
• 104-88-1 4-chlorobenzaldehyde 

Relevant articles and documents

Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives

22 Flavokawain derivatives (FKd) were obtained by one step syntheses in order to conduct a SAR study to understand the structural requirements for optimum and selective cytotoxicity. FKd and natural flavokawains A and B found into kava, a South Pacific traditional beverage, were evaluated against nine cancer and one healthy cell lines. The targeted cell cycle phases as well as the effects on the induction of apoptosis and cell cycle protein levels were investigated. Therapeutic improvements (more activity and selectivity) were achieved with FKd compared to natural flavokawains and notably with the 2′,3,4′,6′-tetramethoxychalcone (FKd 19). FKd induced a G1/S arrest on p53 wild-type cells and an M arrest on p53 mutant-type, via the up-regulation of p21 and cyclin B1 proteins, followed by apoptosis. Moreover, FKd exhibited a 24?h-effect on Akt/mTor normal cells versus a 48?h-effect on Akt/mTor up-regulated cells. The SAR study resulted in the conclusion that trimethoxy A-ring allowed the best compromise between cytotoxicity and selectivity, as well as the substitution of the meta position on the B-ring and the use of halogens substituents.

Trimethoxylated halogenated chalcones as dual inhibitors of mao-b and bace-1 for the treatment of neurodegenerative disorders

Six halogenated trimethoxy chalcone derivatives (CH1–CH6) were synthesized and spec-trally characterized. The compounds were further evaluated for their inhibitory potential against monoamine oxidases (MAOs) and β-secretase (BACE-1). Six compounds inhibit

Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent

The selenoprotein thioredoxin reductases (TrxRs) are attractive targets for anticancer drugs development. Xanthohumol (Xn), a naturally occurring polyphenol chalcone from hops, has received increasing attention because of its multiple pharmacological activities. We synthesized Xn and its 43 analogues and discovered that compound 13n displayed the highest cytotoxicity toward HeLa cells (IC50 = 1.4 μM). Structure-activity relationship study indicates that the prenyl group is not necessary for cytotoxicity, and introducing electron-withdrawing group, especially on the meta-position, is favored. In addition, methylation of the phenoxyl groups generally improves the potency. Mechanistic study revealed that 13n selectively inhibits TrxR and induces reactive oxygen species and apoptosis in HeLa cells. Cells overexpressing TrxR are resistant to 13n insult, while knockdown of TrxR sensitizes cells to 13n treatment, highlighting the physiological significance of targeting TrxR by 13n. The clarification of the structural determinants for the potency would guide the design of novel potent molecules for future development.